This clinical trial is focused on studying the treatment of HIV Disease, specifically in patients who have a very low level of the virus in their blood due to their current treatment. The study will use a combination of two medications: Doravirine and Raltegravir. Doravirine is also known by its code name MK-1439, and Raltegravir is known as MK-0518. These medications are taken as film-coated tablets by mouth.
The purpose of the study is to evaluate how well the combination of Doravirine and Raltegravir can maintain the suppression of the virus in patients who are already successfully managing their HIV with other treatments. Participants will be monitored over a period of time to see if the virus remains suppressed. The study will also look at the health of the immune system by measuring certain types of cells in the blood, and it will assess the quality of life of the participants through questionnaires.
Throughout the study, participants will have regular check-ups to monitor their health and the effectiveness of the treatment. The study will also track any changes in the virus and any potential side effects of the medications. This research aims to provide more information on the effectiveness of this dual therapy in maintaining viral suppression in people living with HIV.



France
Italy
Spain